BWA
TBPH icon

Basecamp Wealth Advisors’s Theravance Biopharma TBPH Stock Holding History

Basecamp Wealth Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$680 Buy
40
+11
+38% +$182 ﹤0.01% 1593
2026
Q1 		$471 Buy
+29
New +$513 ﹤0.01% 1749

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Basecamp Wealth Advisors's TBPH Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Theravance Biopharma (TBPH) stake by 38% in Q2 2026, buying an estimated $182 and bringing the position to 40 shares worth $680. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Basecamp Wealth Advisors first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Basecamp Wealth Advisors held 40 shares of Theravance Biopharma worth $680 as of Q2 2026.
  • Basecamp Wealth Advisors bought 11 Theravance Biopharma shares in Q2 2026, an estimated $182.
  • Theravance Biopharma made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1593 holding.
  • Basecamp Wealth Advisors first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.